Phase I research & development - formulation and analytical development of a multi-dose vial presentation of scopolamine hydrobromide trihydrate containing a antimicrobial preservatives (AMP).
Ended Purchase Order Awarded Last action
- Contract number
- W911SR22P0006
- Awardee
-
CMC Pharmaceuticals, Inc. UEI R9AVS7XL2YB4
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $167,076
Award facts
- Opportunity
-
- Army Applied Small Business Innovation Research (SBIR) Program Broad Agency Announcement (BAA) Special Notice · W50RAJ20S0001 · Posted Sep 25, 2020
- Contract value 100% obligated
- $167,076.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Solon, OH 44139, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
About this award
This firm fixed-price purchase order was awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to CMC Pharmaceuticals, Inc., a woman-owned small business, under the Small Business Innovation Research (SBIR) Program. The $167,076.48 contract is for Phase I research and development to formulate and develop manufacturing processes for a multi-dose vial presentation of scopolamine hydrobromide trihydrate containing antimicrobial preservatives. This award supports the Army's goal of conducting Multi-Domain Operations by 2035 through game-changing soldier capabilities.
Quick answers
Who was awarded contract W911SR22P0006?
W911SR22P0006 was awarded to CMC Pharmaceuticals, Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on February 14, 2022.
How much is contract W911SR22P0006 worth?
The government has obligated $167,076 on W911SR22P0006.
Which agency awarded contract W911SR22P0006?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR22P0006, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911SR22P0006 competed?
The extent of competition for W911SR22P0006 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award